Two-Year Outcomes of Treatment-Experienced Adults after Programmatic Transitioning to Dolutegravir: Longitudinal Data from the VICONEL Human Immunodeficiency Virus Cohort in Lesotho.

Nadine Tschumi,Malebanye Lerotholi,Lipontso Motaboli,Moliehi Mokete,Niklaus D. Labhardt,Jennifer A. Brown

Clinical infectious diseases/Clinical infectious diseases (Online University of Chicago Press)（2023）

引用 0|浏览7

暂无评分

摘要

In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and 95.4% before, 12 months after, and 24 months after transition, respectively. Sex, age, pretransition viral load, and treatment backbone correlated with 24-month viremia.

查看译文

关键词

Africa,integrase inhibitors,treatment outcome,treatment failure,observational study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要